Video

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Two large trials were presented at the 2018 ASCO Annual Meeting and the 2018 European Hematology Association Congress that used pomalidomide (Pomalyst) as part of a triplet regimen, says Lonial. The first trial, known as OPTIMISMM, examined the combination of pomalidomide, bortezomib (Velcade), and dexamethasone (PVd) versus bortezomib and low-dose dexamethasone (Vd) alone. The phase III trial was conducted in patients with relapsed/refractory myeloma with prior exposure to lenalidomide (Revlimid), explains Lonial.

The trial showed a median progression-free survival (PFS) of 11.20 months with PVd compared with 7.10 months with bortezomib and low-dose dexamethasone (Vd) alone (HR, 0.61; 95% CI, 0.49-0.77; P <.0001).

ELOQUENT-3 looked at the addition of elotuzumab (Empliciti) to pomalidomide and dexamethasone and found that the regimen cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone. Median PFS was 10.3 months (95% CI, 5.6-not evaluable) with the elotuzumab combination compared with 4.7 months (95% CI, 2.8-7.2) with pomalidomide plus dexamethasone (HR, 0.54; 95% CI, 0.34-0.86; P = .0078). The results of the trial put the regimen alongside daratumumab (Darzalex), pomalidomide, and dexamethasone, says Lonial. This suggests that if patients get daratumumab earlier, elotuzumab, pomalidomide, and dexamethasone would be a good salvage therapy.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD